Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Featured News Medtronic Stock Finds Its Footing—Now It's Gaining MomentumWritten by Thomas Hughes. Published 11/19/2025. 
Key Points - Medtronic's turnaround has taken time, but it is here and gaining momentum.
- Analysts and institutional trends indicate accumulation underway.
- Q2 results and the guidance update affirm strength and capital returns in F2026 and beyond.
Medtronic (NYSE: MDT) took considerable time to regain momentum, but it has — and the stock now looks poised to move higher. The chart reflects this shift, showing a bottoming process unfolding over several years. Forget ChatGPT.
Musk's new AI is built to be 100x more powerful, working in the real world.
Join now to get the full report + all 6 bonuses before the sale ends.
Our Black Friday sale expires soon and with it, your chance to get VIP Unlimited access for $79 and uncover Elon's #1 AI Stock to Buy ASAP! Get the details here >>> Key developments: price cleared a crucial hurdle in early 2025, a Golden Crossover formed, and a market reversal was confirmed following the fiscal 2026 (F2026) Q2 earnings release. In this scenario, MDT looks set to rally over coming quarters — potentially years — supported by modest growth, healthy margins, strong cash flow, and ongoing capital returns. 
Medtronic's stock price could advance 20% to 30%, potentially more, given the favorable growth outlook. The company is sustaining mid-single-digit growth in F2026, and results are accelerating, prompting guidance improvements and a strong chance that current forecasts are conservative. As of mid-November, the consensus forecasts reported by MarketBeat expect the healthcare company to grow at a mid-single-digit pace over the next five to six years, with incremental margin improvements. Capital returns are a significant factor, including dividends, dividend growth, and share buybacks. The dividend yield of 2.95% is attractive and well-supported; the payout ratio is about 50%, making the current payment sustainable. Further distribution increases are likely because the company is a Dividend Aristocrat with more than 40 consecutive years of dividend increases, backed by earnings growth and a healthy balance sheet. Share buybacks are also steadily reducing the share count each quarter and are expected to continue at this pace for the foreseeable future. Medtronic Fires on All Cylinders in Q2 F2026 Medtronic posted a strong fiscal Q2, delivering $8.96 billion in net revenue — a 6.6% year-over-year increase that accelerated from the prior year and slightly outpaced consensus. Strength was broad-based. Organic growth rose 5.5%, the Cardiovascular portfolio grew 10.8% driven by a 71% increase in cardiac ablation solution sales, and Diabetes sales climbed 10.3% year-over-year, with smaller gains in Neurosciences and Medical-Surgical. Margin news is also good. Operational quality and the absence of tariff surprises contributed to incremental margin improvement and stronger bottom-line gains. Adjusted earnings grew about 8%, outpacing the 6.6% revenue gain and beating MarketBeat's reported consensus by a wider margin; that strength appears likely to continue. Q2 results prompted management to raise its guidance for the year, which boosted market sentiment. The company increased its organic growth forecast by 50 basis points to 5.5% — slightly ahead of consensus — and nudged the midpoint of its EPS range above consensus. Management may raise targets again after FQ3. Institutional and Analyst Trends Indicate Accumulation Underway Institutional and analyst trends indicate accumulation of MDT shares is underway. Institutions — which own more than 80% of the stock — have been buying consistently over the past 12 months and stepped up purchases in late Q3 and early Q4. Those institutional positions provide a solid support base and a market tailwind, a pattern also visible in analyst data. Analyst trends show expanded coverage, firmer sentiment, and rising price targets; the consensus price target of $103 implies modest upside, while recent updates point to larger potential gains. The question is whether institutions and analysts will continue to buy and raise targets — the Q2 developments suggest they will. Post-release price action was solid. The stock jumped roughly 5% soon after the open, confirming support at a key pivot and setting a new high. That pivot — prior resistance at the top of a trading range — serves as the baseline for the reversal. In short, the technical reversal appears complete, opening the door to a sustainable rally.
| 
Post a Comment
Post a Comment